Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema

References

• Chan A, Duker JS, Ko TH, et al. Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 2006;124:193-8
   PubMedGoogle Scholar
• Alamouti B, Funk J. Retinal thickness decreases with age: an OCT study. Br J Ophthalmol 2003;87:899-901
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016;123:1351-9
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt vs. deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122:375-81
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-203
   PubMed Web of Science ®Google Scholar
• Holden SE, Currie CJ, Owens DR. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Curr Med Res Opin 2017;33(Suppl):5--17
   PubMed Web of Science ®Google Scholar
• Haukoos JS, Newgard CD. Advanced statistics: missing data in clinical research—part 1: an introduction and conceptual Framework. Acad Emerg Med 2007;14:662-8
   PubMed Web of Science ®Google Scholar
• Wolf-Schnurrbusch UEK, Ceklic L, Brinkmann CK, et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009;50:3432-7
   PubMed Web of Science ®Google Scholar
• Sandberg MA, Brockhurst RJ, Gaudio AR, et al. The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 2005;46:3349-54
   PubMed Web of Science ®Google Scholar
• Danis RP, Sadda S, Jiao J, et al. Relationship between retinal thickness and visual acuity in eyes with retinal vein occlusion treated with dexamethasone implant. Retina 2016;36:1170-6
   PubMed Web of Science ®Google Scholar
• Ristau T, Keane PA, Walsh AC, et al. Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. Ophthalmologica 2014;231:37-44
   PubMed Web of Science ®Google Scholar
• Hannouche RZ, De Avila MP. Retinal thickness measurement and evaluation of natural history of the diabetic macular edema through optical coherence tomography. Arq Bras Oftalmol 2009;72:433-8
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. The relationship between OCT-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-36
   PubMed Web of Science ®Google Scholar
• Noda Y, Ogawa A, Toyama T, et al. Long-term increase in subfoveal choroidal thickness after surgery for senile cataracts. Am J Ophthalmol 2014;158:455-9
   PubMed Web of Science ®Google Scholar
• Treumer F, Wacker N, Junge O, et al. Foveal structure and thickness of retinal layers long-term after surgical peeling of idiopathic epiretinal membrane. Invest Ophthalmol Vis Sci 2011;52:744-50
   PubMed Web of Science ®Google Scholar
• Yang Y, Bailey C, Holz FG, et al. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye 2015;29:1173-80
   PubMed Web of Science ®Google Scholar
• Takahashi A, Nagaoka T, Sato E, et al. Effect of panretinal photocoagulation on choroidal circulation in the foveal region in patients with severe diabetic retinopathy. Br J Ophthalmol 2008;92:1369-73
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). 12-month data: report 2. Ophthalmology 2010;117:1078-86
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009;116:2175-81
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg J, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study*). A 12-month randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-405
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Ranibizumab for treating diabetic macular oedema. Technology appraisal guidance [TA274]; 2013. Available at: https://www.nice.org.uk/guidance/ta274. [Last accessed February 27, 2013]
   Google Scholar
• National Institute for Health and Care Excellence. Aflibercept for treating diabetic macular oedema. Technology appraisal guidance [TA346]; 2015. Available at: https://www.nice.org.uk/guidance/ta346. [Last accessed May 8, 2016]
   Google Scholar
• National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy; 2013. Available at: www.nice.org.uk/guidance/ta301. [Last accessed October 24, 2014]
   Google Scholar
• El-Ghrably I, Steel DHW, Habib M, et al. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience. Eur J Ophthalmol 2017;27:357-62
   PubMed Web of Science ®Google Scholar
• Elaraoud I, Andreatta W, Kidess A, et al. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol 2016;16:3
   PubMed Web of Science ®Google Scholar
• Figueira J, Henriques J, Amaro M, et al. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res 2017;57:166-72
   PubMed Web of Science ®Google Scholar
• Massin P, Erginay A, Dupas B, et al. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol 2016;10:1257-64
   PubMed Web of Science ®Google Scholar